Authors
Satveer K Mahil, Katie Bechman, Antony Raharja, Clara Domingo-Vila, David Baudry, Matthew A Brown, Andrew P Cope, Tejus Dasandi, Carl Graham, Thomas Lechmere, Michael H Malim, Freya Meynell, Emily Pollock, Jeffery Seow, Kamila Sychowska, Jonathan N Barker, Sam Norton, James B Galloway, Katie J Doores, Timothy IM Tree, Catherine H Smith
Publication date
2021/9/1
Journal
The Lancet Rheumatology
Volume
3
Issue
9
Pages
e627-e637
Publisher
Elsevier
Description
Background
Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses to COVID-19 vaccine BNT162b2 (Pfizer-BioNTech) in patients taking methotrexate and commonly used targeted biological therapies, compared with healthy controls. Given the roll-out of extended interval vaccination programmes to maximise population coverage, we present findings after the first dose.
Methods
In this cohort study, we recruited consecutive patients with a dermatologist-confirmed diagnosis of psoriasis who were receiving methotrexate or targeted biological monotherapy (tumour necrosis factor [TNF] inhibitors, interleukin [IL]-17 inhibitors, or IL-23 inhibitors) from a specialist psoriasis centre serving London and South East England. Consecutive volunteers without psoriasis and not …
Scholar articles
SK Mahil, K Bechman, A Raharja, C Domingo-Vila… - The Lancet Rheumatology, 2021